Urticaria | Treatment Algorithms: Claims Data Analysis | Chronic Spontaneous | US | 2021
The drug market for chronic spontaneous urticaria (CSU), previously know as chronic idiopathic urticaria, is dominated by oral medications, including first- and second-generation (nondrowsy) antihistamines, off-label DMARDs, immunosuppressants, and tricyclic antidepressants. However, several drug classes have serious side effects, and many patients still struggle to control their lesions. As a result, the approval of Novartis / Roche’s Xolair was welcomed, but the high cost limits access for many patients. Guidelines for CSU were recently updated to remove montelukast and prioritize prescription therapies, but some physicians have been slow to adapt.
QUESTIONS ANSWERED
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed CSU patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed CSU patients?
- Has Xolair continued to gain patient share? Following montelukast’s removal from guidelines, how has its patient share changed?
- What percentage of CSU patients receive drug therapy within 365 days of diagnosis? What percentage of patients progress to later lines of therapy?
- What percentage of patients are treated with monotherapy versus combination therapy? What are the most widely used combinations?
- What are the product-level compliance and persistency rates among drug-treated CSU patients?
Product Description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
